Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial ...
BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027 ...
BV500: Entered global research collaboration with Shionogi for broad-spectrum non-tuberculous mycobacteria Successful IPO funding operations into 2028 with BV100 Phase 3 read-out by the end of 2027 ...
Hosted on MSN
BioVersys secures patent claims in China for BV100
Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous formulation of rifabutin. The technology is being developed to combat resistant ...
Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China BV100 patents have now been granted in over 25 ...
BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose-proportional pharmacokinetic profile and was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results